In this episode of MedTech Global Insights, we dissect the FDA's unexpected new mandatory cybersecurity rules for connected medical devices. What was once guidance is now a critical requirement for market access, demanding continuous post-market surveillance and proactive threat modeling that has left many manufacturers scrambling to adapt.

We explore the immediate consequences for startups, mid-size companies, and large enterprises, who now face significant unplanned costs and logistical challenges. A European company, for example, believed its FDA submission for an already EU-approved device was straightforward. Now, they are forced to halt their U.S. launch to build a completely new, five-year cybersecurity plan from scratch, jeopardizing investor timelines and market entry.

Key Takeaways:

- Why is the FDA’s new guidance more than just a simple document update?

- What are the three most critical components of the new mandatory surveillance plan?

- How does this rule change the budget for a medical device startup overnight?

- What steps must companies with existing products on the market take immediately?

- How can you turn this new regulatory burden into a competitive advantage?

- What are the key differences between the FDA’s new rules and EU MDR cybersecurity requirements?

- How can AI-powered tools help automate the new threat modeling and documentation demands?

For more information, contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and medical device database at https://pureglobal.ai/.